Biosimilars Approval to Biogenerics in Clinical Practice

Biological medicines are much more structurally complex and extremely sensitive to manufacturing conditions and therefore more difficult to characterize and produce than small molecule drugs. Even minor changes in manufacturing may lead to significant variations of the cellular systems used for biological production, as well as to differences in the structure, stability, or other quality aspects of the end product, all of which have the potential to affect tolerability and/or efficacy and increase the risk of immune responses. Owing to these issues, specific regulatory guidance on biosimilars is continuously evolving, and there is some disagreement on which studies need to be implemented to approve a biosimilars. According to current literature, the following points on biosimilars deserve consideration: Biosimilars development is characterized by global harmonization, although several not fully answered questions remain regarding extrapolation of indications, switching or interchange ability, and tolerability; in patients with rheumatic diseases, the tolerability and efficacy of biosimilars in clinical practice remain to be established; several medical and patient associations have published position papers on biosimilars requesting that safety, efficacy, and traceability be carefully considered; long-term post marketing studies should be implemented to allow physicians to gain confidence in biosimilars.

  • Biotechnologic drug
  • Monoclonal antibody
  • Fusion protein
  • Biologic drug
  • Anti–tumor necrosis factor

Related Conference of Biosimilars Approval to Biogenerics in Clinical Practice

Pharmacology 2020

Barcelona, Spain
October 14-15, 2019

19th World Congress on Advances in Pharmaceutical Sciences

Seoul, South Korea
October 25-26, 2019

14th International Conference on Biopharma and Biotherapeutics

| Copenhagen, Denmark
October 23-24, 2019 | Copenhagen, Denmark

12th Pharma Congress

September 11-12, 2019

2nd Annual Pharmaceutical Biotechnology Congress

Singapore
November 11-12, 2019

20th Annual Pharma Middle East Congress

Renaissance Polat Istanbul Hotel | Istanbul, Turkey
November 18-19, 2019

European Congress on Nanomedicine and Pharmaceutical Nanotechnology

Prague, Czech Republic
November 18-19, 2019

European Conference on Pharmacovigilance & Drug Safety

Prague, Czech Republic
November 19-20, 2019

20th Annual Meet on Pharmaceutical Sciences

Bangkok, Thailand
December 02-03, 2019

15th Annual Congress on Pharmacology and Toxicology

Paris, France
February 12-13, 2020

14th Global Pharmacovigilance and Clinical Trials Summit

Sydney, Australia
February 12-13, 2020

2nd International Conference on Biosimilars & Pharmaceuticals

Auckland, New Zealand
March 23- 24, 2020

14 th World Drug Delivery Summit

| Dublin, Ireland
March 25-26, 2020

23rd Asia Pacific Pharma Congress

Singapore
April 01-02, 2020

13th European Biosimilars Congress 2020

London, UK
April 09-10, 2020

World Pharma Expo

Bangkok, Thailand
April 27-28, 2020

5th Pharmaceutical Chemistry Conference

Prague, Czech Republic
April 27-28, 2020

7th European Biopharma Congress

Prague, Czech Republic
May 06-07, 2020

15th Annual Meet on Euro Ethnopharmacology

Prague | Czech Republic
May 18-19, 2020

30th Annual European Pharma Congress

Berlin, Germany
October 19-20, 2020

Innovation in Drug Design Techniques and Pharmacology

| Paris, France
December 02-03, 2020

International Conference onBiotechnology and Healthcare

Auckland, Newzealand
December 06-07, 2021

22nd Pharma Middle East Congress

Dubai, UAE

Biosimilars Approval to Biogenerics in Clinical Practice Conference Speakers

Recommended Sessions

Related Journals

Are you interested in